Diabetes: Anvisa Approves New Medicine that Combines Insulin and Semaglutide
6 Articles
6 Articles
semaglutide, ozempic Freepik The National Agency for Health Surveillance (Anvisa) approved the registration of Kyinsu, a medicine of the New Nordisk that combines insulin icodeca and semaglutide in a single solution for injection. The decision was published in the Official Journal of the Union (DOU) on Monday (28). According to the European Medicines Agency, Kyinsu is a medicine used in the treatment of type 2 diabetes. It is recommended mainly …
Kyinsu is indicated for adults with type 2 diabetes and gathers in a single weekly application basal insulin and GLP-1 agonist. Read on Power360.
Medicinal product, known as Kyinsu, is usually recommended for use in adults with the disease.
Diabetes type 2 is a chronic disease marked by high blood glucose levels
Kyinsu combines the two active principles and is indicated for adults who have type 2 diabetes
Medicinal product approved by Anvisa binds two types of treatment in a single weekly application for type 2 diabetes control
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
